Advertisement
GSK vs NVS
Which Stock Would AI Choose? GSK plc (GSK) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- GSK is executing a specialty-medicines turnaround under new leadership, while NVS is navigating the largest patent expiration in its history against a backdrop of recent clinical setbacks.
- Both stocks carry patent-cliff risk, but their growth engines differ sharply: GSK leans on HIV, oncology, and vaccines, while Novartis leans on oncology, immunology, and cardiovascular medicine.
- Recent sentiment has favored GSK's steady operational delivery over Novartis's choppier news flow, which included disappointing trial data and governance criticism.
- Valuation and income profiles diverge, with GSK offering a higher dividend yield at a lower earnings multiple, and Novartis trading at a premium multiple with a more modest yield.
- Relative performance over recent months has tilted toward GSK, though both are large, defensive pharmaceutical names with global diversification.
- For more detail, explore GSK Major News and GSK Today's Price Move, or NVS Major News and NVS Today's Price Move.
- To see how automated strategies are positioning across these and other names, explore the Trending AI Robots.
Introduction
GSK plc and Novartis AG are two of the world's largest pharmaceutical companies, but they sit at very different points in their strategic cycles. This stock comparison is most relevant for investors and traders weighing defensive healthcare exposure against growth-stage execution risk, as both firms face patent expirations while investing heavily to refresh their pipelines. Because the two companies operate in overlapping therapeutic areas, their relative performance offers a useful lens on how the market is pricing near-term catalysts, pipeline durability, and capital returns. Understanding their distinct market positioning can help readers assess which profile better fits their own objectives.
GSK Overview and Recent Performance
GSK plc, headquartered in the United Kingdom, is a global biopharmaceutical company spanning specialty medicines, vaccines, and general medicines. Recent market activity has been shaped by a leadership transition, with Luke Miels taking over as chief executive at the start of 2026. Under his direction, the company has reaffirmed 2026 guidance for 3% to 5% sales growth and 7% to 9% growth in core operating profit and core earnings per share (EPS).
In recent quarters, GSK delivered strong results from its specialty medicines franchise, with double-digit growth in oncology and HIV, and announced a £1.9 billion cost-savings program alongside plans to start more than 20 late-stage Phase III clinical trials in 2026. Despite these beats, the shares have traded below their 52-week high, reflecting investor concern about the approaching loss of exclusivity on dolutegravir, its key HIV medicine, expected between 2028 and 2030. The company targets more than £40 billion in annual sales by 2031.
NVS Overview and Recent Performance
Novartis AG, based in Basel, Switzerland, is a global innovator focused on prescription medicines across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. The company is currently working through what management has called the largest patent expiry in its history, as generic competition pressures older brands such as Entresto and Promacta.
Novartis's growth drivers have performed well in recent quarters, with strong sales momentum from Kisqali (breast cancer), Kesimpta (multiple sclerosis), Pluvicto (prostate cancer), Leqvio, and Scemblix. However, recent weeks have brought a more mixed news flow. Full data for its investigational multiple sclerosis pill remibrutinib showed relapse-rate reductions below those reported by Roche's competing drug, and the shares pulled back. The company has also absorbed earlier trial setbacks and public calls from a major shareholder for board-level changes. These developments have tempered sentiment despite solid underlying revenue growth.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a broader library of hundreds of automated strategies that collectively trade thousands of tickers, including GSK and NVS. Only the bots best suited to current market conditions earn a place in this section. Each bot operates with its own trading style, strategy, timeframe, performance history, and set of covered tickers, giving traders the flexibility to match automation to their own objectives. Reviewing these tools can provide a data-driven complement to fundamental stock comparison. Explore the Trending AI Robots page to see which strategies are currently leading.
Head-to-Head Comparison
The most important contrast between GSK and NVS is the timing and severity of their patent cliffs. GSK's key dolutegravir exclusivity loss arrives later in the decade, giving it a runway to scale its oncology and specialty pipeline, while Novartis is already absorbing generic erosion and counting on growth drivers to offset it. This timing difference is reflected in market positioning: GSK's execution has been relatively consistent, whereas Novartis has faced greater event-driven volatility from clinical readouts and governance scrutiny.
Their business models also differ. GSK retains a meaningful vaccines and general medicines franchise alongside specialty medicines, while Novartis is more heavily concentrated in innovative prescription medicines. On valuation and income, GSK has traded at a lower price-to-earnings ratio with a higher dividend yield, while Novartis commands a premium multiple with a more modest yield. Risk factors overlap—pricing policy, regulatory decisions, and trial outcomes—but Novartis's recent M&A (mergers and acquisitions) execution has drawn more investor criticism, whereas GSK's primary concern is replacing its HIV franchise before patent expiry.
Tickeron AI Verdict
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI would likely favor GSK over NVS in the current environment. GSK's steadier operational delivery, reaffirmed guidance, and more distant patent cliff present a comparatively smoother trend profile, whereas Novartis's recent clinical disappointments and governance headlines have introduced greater uncertainty into its near-term momentum. That said, Novartis retains strong growth drivers that could reassert leadership if upcoming catalysts land favorably. The assessment is probabilistic rather than definitive, and both names carry meaningful binary event risk tied to pipeline outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and NVS is a Hold.
GSK in -1.60% downward trend, falling for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GSK declined for three days, in 159 of 287 cases, the price declined further within the following month. The odds of a continued downward trend are 55%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In 37 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GSK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GSK's RSI Indicator exited the oversold zone, 15 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on November 04, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 30 of 46 cases over the following month. The odds of a continued upward trend are 65%.
GSK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.715) is normal, around the industry mean (-1.360). P/E Ratio (20.988) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.036) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
NVS in upward trend: 10-day moving average broke above 50-day moving average on October 22, 2026
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 43 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 187 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.360). P/E Ratio (24.370) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).
GSK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 35 | 4 | |
SMR RATING 1..100 | 34 | 33 | |
PRICE GROWTH RATING 1..100 | 47 | 40 | |
P/E GROWTH RATING 1..100 | 8 | 13 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (54) in the Pharmaceuticals Major industry is in the same range as GSK (81). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as GSK (35). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is in the same range as GSK (34). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
NVS's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as GSK (47). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
GSK's P/E Growth Rating (8) in the Pharmaceuticals Major industry is in the same range as NVS (13). This means that GSK’s stock grew similarly to NVS’s over the last 12 months.
| GSK | NVS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 65% | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 33% | 1 day ago 38% |
| Momentum ODDS (%) | 1 day ago 48% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 65% | N/A |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 59% | 1 day ago 51% |
| Advances ODDS (%) | 23 days ago 63% | 12 days ago 55% |
| Declines ODDS (%) | 1 day ago 55% | N/A |
| BollingerBands ODDS (%) | 1 day ago 42% | 1 day ago 30% |
| Aroon ODDS (%) | 1 day ago 46% | 1 day ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green while NVS’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 5 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
- GSK’s TA Score: 5 bullish, 5 bearish.
- NVS’s TA Score: 5 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +1.66% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
Reported Earning Dates
GSK is expected to report earnings on Feb 03, 2027.
NVS is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.